biotech firm’s stock rides on avutometinib approval By Investing.com
Verastem Inc (NASDAQ:), a biopharmaceutical company with a market capitalization of $289 million focused on developing treatments for cancer patients, stands at a critical juncture as it approaches a potentially transformative year in 2025. The company’s stock has shown remarkable momentum, delivering a 145% return over the past six months according to InvestingPro data. The company’s future hinges largely on the success of its lead candidate, avutometinib, for the treatment of KRAS-mutant low-grade serous ovarian cancer (LGSOC). As Verastem navigates the regulatory landscape and prepares for potential commercialization, investors and analysts are closely watching the company’s progress.
Company Overview
Verastem is a biotech firm…
